{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T12:18:43Z","timestamp":1788005923182,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Vivesto"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04933-6","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T11:47:04Z","timestamp":1788004024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67\/20 trial"],"prefix":"10.1007","volume":"96","author":[{"given":"Ilaria","family":"Colombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale C. S.","family":"Rietveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cathomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L. W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Zoelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Gobat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Micheloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelius","family":"Omlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Joerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"4933_CR1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163\u20131177","journal-title":"Lancet"},{"key":"4933_CR2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513\u20131520","journal-title":"N Engl J Med"},{"key":"4933_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373:737\u2013746","journal-title":"N Engl J Med"},{"key":"4933_CR4","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502\u20131512","journal-title":"N Engl J Med"},{"key":"4933_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED et al (2022) Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 386:1132\u20131142","journal-title":"N Engl J Med"},{"key":"4933_CR6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A et al (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised,phase 3 study with a 2\u2009\u00d7\u20092 factorial design. Lancet 399:1695\u20131707","journal-title":"Lancet"},{"key":"4933_CR7","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.1998.16.10.3426","volume":"16","author":"KA Semb","year":"1998","unstructured":"Semb KA, Aamdal S, Oian P (1998) Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16:3426\u20133432","journal-title":"J Clin Oncol"},{"key":"4933_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/1078155210367950","volume":"17","author":"JD Chouhan","year":"2011","unstructured":"Chouhan JD, Herrington JD (2011) Single premedication dose of dexamethasone 20\u00a0mg IV before docetaxel administration. J Oncol Pharm Pract 17:155\u2013159","journal-title":"J Oncol Pharm Pract"},{"key":"4933_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00520-002-0405-9","volume":"11","author":"M Markman","year":"2003","unstructured":"Markman M (2003) Managing taxane toxicities. Support Care Cancer 11:144\u2013147","journal-title":"Support Care Cancer"},{"key":"4933_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","volume":"335","author":"AE Coutinho","year":"2011","unstructured":"Coutinho AE, Chapman KE (2011) The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 335:2\u201313","journal-title":"Mol Cell Endocrinol"},{"key":"4933_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP van Staa","year":"2002","unstructured":"van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777\u2013787","journal-title":"Osteoporos Int"},{"key":"4933_CR12","doi-asserted-by":"crossref","unstructured":"Joerger M, Bjermo H, Blom P, Heldring NA (2020) Pharmacokinetics, safety, and early activity of a nanoparticle micellar formulation of docetaxel in women with metastatic breast cancer: Results of two randomized trials (phase I and II). J Clin Oncol. 38:3526-3526","DOI":"10.1200\/JCO.2020.38.15_suppl.3526"},{"key":"4933_CR13","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-005161-12\/results; access on September 22 2025."},{"key":"4933_CR14","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G et al (2020) Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1119\u20131134","journal-title":"Ann Oncol"},{"key":"4933_CR15","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K et al (2016) Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34:1402\u20131418","journal-title":"J Clin Oncol"},{"key":"4933_CR16","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/bcp.13889","volume":"85","author":"BPS Belderbos","year":"2019","unstructured":"Belderbos BPS, Hussaarts K, van Harten LJ, Oomen-de Hoop E, de Bruijn P, Hamberg P et al (2019) Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study. Br J Clin Pharmacol 85:986\u2013992","journal-title":"Br J Clin Pharmacol"},{"key":"4933_CR17","volume-title":"M10 Bioanalytical Method Validation and Study Sample Analysis","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)","year":"2022","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2022) M10 Bioanalytical Method Validation and Study Sample Analysis. ICH, Geneva, Switzerland"},{"key":"4933_CR18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1023\/A:1012258723075","volume":"12","author":"TM Beer","year":"2001","unstructured":"Beer TM, Pierce WC, Lowe BA, Henner WD (2001) Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12:1273\u20131279","journal-title":"Ann Oncol"},{"key":"4933_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0093-7754(01)90149-6","volume":"28","author":"W Berry","year":"2001","unstructured":"Berry W, Dakhil S, Gregurich MA, Asmar L (2001) Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28:8\u201315","journal-title":"Semin Oncol"},{"key":"4933_CR20","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/bjc.1996.416","volume":"74","author":"V Dieras","year":"1996","unstructured":"Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL et al (1996) A multicentre phase II study of docetaxel 75\u00a0mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. Br J Cancer 74:650\u2013656","journal-title":"Br J Cancer"},{"key":"4933_CR21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/87551225221116266","volume":"38","author":"EJ Koshi","year":"2022","unstructured":"Koshi EJ, Young K, Mostales JC, Vo KB, Burgess LP (2022) Complications of Corticosteroid Therapy: A Comprehensive Literature Review. J Pharm Technol 38:360\u2013367","journal-title":"J Pharm Technol"},{"key":"4933_CR22","doi-asserted-by":"publisher","first-page":"104956","DOI":"10.1016\/j.cellimm.2025.104956","volume":"411\u2013412","author":"J Yan","year":"2025","unstructured":"Yan J, Choi K, Fu P, Yang M, Lin J, Gui M et al (2025) The real-world impact of corticosteroid-associated adverse events in myasthenia gravis: A patient-reported survey analysis. Cell Immunol 411\u2013412:104956","journal-title":"Cell Immunol"},{"key":"4933_CR23","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-08-2131","volume":"15","author":"A Melhem","year":"2009","unstructured":"Melhem A, Yamada SD, Fleming GF, Delgado B, Brickley DR, Wu W et al (2009) Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1\/DUSP1 in ovarian tissues. Clin Cancer Res 15:3196\u20133204","journal-title":"Clin Cancer Res"},{"key":"4933_CR24","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.18632\/oncotarget.27989","volume":"12","author":"AE Greenstein","year":"2021","unstructured":"Greenstein AE, Hunt HJ (2021) Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells. Oncotarget 12:1243\u20131255","journal-title":"Oncotarget"},{"key":"4933_CR25","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","volume":"405","author":"AB Olawaiye","year":"2025","unstructured":"Olawaiye AB, Gladieff L, O\u2019Malley DM, Kim J-W, Garbaos G, Salutari V et al (2025) Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. Lancet 405:2205\u20132216","journal-title":"Lancet"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04933-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04933-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04933-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T11:47:05Z","timestamp":1788004025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04933-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4933"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04933-6","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I Colombo\n                      : Travel grants: Tesaro, Janssen, AZ, GSK; Honoraria for consultancy or expert opinion: AZ, GSK, Novartis, MSD, BionTech, Abbvie, Beigene, Incyte, Daiichi Sanyo; Institutional grants for clinical trials (PI): MSD, Bayer, Vivesto, Incyte, AZ, Orion, Tolremo, Debio.\n                      PCS Rietveld\n                      : No competing interest to declare.\n                      S Fischer\n                      : Speaker\u2019s bureau: Johnson & Johnson (compensated, institutional); Travel support: Bayer; Research grant: Astellas, MSD; Medical Advisor\/Steering Committee member: AMGEN (compensated, institutional)\n                      S Merlo\n                      : No competing interest to declare.\n                      U Vogl\n                      : Speaker or consultancy honoraria from Accord (P), Astellas (I, P), Astra Zeneca (I), Bayer (I,P), European School of Oncology (ESO) (I) The healthbook Times (I, P) Janssen Cielag (I), Merck (I), MSD (I), Novartis AAA (I), Oncology Compass (I), SAKK (I), SAMO (I, P), travel grants from Astra Zeneca, Janssen, Merck and Ipsen (P), Grant Funding from Fond'Action Research Grant (I). SAKK PG UG president and Editor in Chief of the Healthbook Times.\n                      R Cathomas\n                      : Advisory role (institutional): Astellas, Astra Zeneca, Pfizer, BMS, MSD, Roche, Merck, Johnson &Johnson,Ipsen, Accord; speaker role (institutional): Astellas, Merck, Ipsen, Johnson & Johnson, Accord; travel support (insitutional): Astra Zeneca, Ipsen.\n                      S Koolen\n                      : Honoraria for consultancy: NaDeNo (paid to institution).\n                      D Zoelly\n                      : No competing interest to declare.\n                      K Gobat\n                      : No competing interest to declare.\n                      C Micheloud\n                      : No competing interest to declare.\n                      K Eckhardt\n                      : No competing interest to declare.\n                      C Sessa\n                      : No competing interest to declare.\n                      A Stathis\n                      : Institutional funding for clinical trials: from Abbvie, ADC Therapeutics, Amgen, Astra Zeneca, Bayer, BMS, Cellestia, Debiopharm, Incyte, Loxo Oncology, MSD, Novartis, Nurix Therapeutics, Pfizer, Philogen, Prelude Therapeutics, Roche. Consultant\/expert testimony\/advisory board: (institutional): Debiopharm, Janssen, AstraZeneca, Incyte, Eli Lilly, Novartis, Roche, Loxo Oncology; (personal): Incyte. Travel grant: Incyte; Astra Zeneca.\n                      A Omlin\n                      : Advisory role: (compensated, institutional): Abbvie, Accord, Advanced accelerator applications (AAA), Astra Zeneca, Astellas, Bayer, Janssen, Monrol, Merck, MSD, Myriad, Novartis, Pfizer, Roche. Travel support: Astellas, Bayer, Janssen.\n                      M Joerger\n                      : institutional consultant\/advisory fees from Roche, Johnson&Johnson, Astra Zeneca, Bayer, BMS, MSD; investigator in clinical trials for AstraZeneca, Bayer, BMS, Daiichi Sankyo, Immunophotonics, Innomedica, Lilly, MSD, Novartis, Intensity Therapeutics, Roche, Sanofi, Takeda, Incyte, Debiopharm, Anaveon; travel grants from Sanofi, Roche.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"95"}}